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statins have been widely investigated, and their use is usually
recommended in the secondary prevention of acute coronary
syndrome (ACS). To investigate the use of statins for the
primary prevention of ACS, between April 2004 and February
2005 we enrolled a total of 31 end-stage renal disease patients
on MHD, with neither history nor clinical and instrumental
signs of earlier major adverse cardiac events (MACEs). We
started each patient on atorvastatin (10 mg) daily regardless
of serum low-density lipoprotein cholesterol associated with
conventional pharmacologic control of blood pressure, serum
glucose, and calcium–phosphate balance. During a 4-year
follow-up overall 3-year actuarial survival was 67%,3
compared with a 20–40% 5-year survival reported earlier.4
Cardiovascular mortality was 12.9%, (4 patients). ‘MACE’
free’ (lethal and non-lethal) 3-year actuarial survival was
53%. Treatment with statins may be considered in the
primary prevention of MACEs in hemodialysis patients.
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Considering the clinical benefits of statins for primary
and secondary cardiovascular event prevention in normal
renal function patients, one can assume a similar benefit
for patients with chronic kidney disease. Accordingly,
Manca-di-Villahermosa’s letter1 reports that a small group
of end-stage renal disease patients receiving atorvastatin
show low cardiovascular mortality after 3 years of follow-
up. However, in the 4-D study—the only randomized
placebo-controlled statin trial done to date, which
included 1255 patients with type 2 diabetes undergoing
hemodialysis—atorvastatin administration was not
associated with cardiovascular mortality reduction, which
accounts for half the deaths in such patients.2 Moreover,
this occurs independently of the presence or absence of
high c-reactive protein levels that are associated with
cardiovascular event risk.3 Reasons for this discrepancy are
not evident, as statins exert anti-inflammatory, antiox-
idant, and lipid-lowering effects as effective as those
observed in normal renal function participants. End-stage
renal disease patients are at high risk for cardiovascular
complications, in whom cardiovascular disease is con-
sidered complex and aggravated by coexisting factors,
including malnutrition, accelerated atherosclerosis, left
ventricular hypertrophy, cardiac fibrosis, and sympathetic
overactivity. In the 4-D study, most of cardiovascular
deaths were caused by sudden death and not by coronary
heart disease.2 Data for two ongoing large trials (AURORA
and SHARP) would help put into perspective statin’s
beneficial effect in chronic kidney disease with respect to
cardiovascular mortality. Apart from this, it has been
reported that statin use is associated with sepsis incidence
reduction—a major cause of morbimortality in chronic
kidney disease.4 This protective benefit could contribute to
total mortality reduction in peritoneal dialysis and
hemodialysis patients using statins reported by some
observational studies (e.g., DOPPS).5
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To the Editor: Phosphonoformic acid (PFA) is a non-
hydrolyzeable inorganic pyrophosphate analog, and it
has been used as an experimental inhibitor of renal and
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